SecBot SecBot
SECBOTREPLAY Home › Report › RYTM

RYTM · Rhythm Pharmaceuticals presented positive clinical data for…

Rhythm Pharmaceuticals, Inc. · PRESS-RELEASE filed May 12, 2026 at 08:00 ET

At the news

NEUTRALIMPACT 4/10

PRESS-RELEASE filed May 12, 2026 at 08:00 ET

Rhythm Pharmaceuticals presented positive clinical data for setmelanotide at ECE 2026, including significant BMI reductions (16.9% at 12 months) and improvements in cardiometabolic risk indices in acquired hypothalamic obesity. The data are encouraging but represent incremental conference presentations rather than a regulatory or financial catalyst.

  • Real-world data showed 16.9% mean BMI reduction at 12 months in acquired HO (n=25, p<0.0001).
  • Phase 3 TRANSCEND post hoc analysis: metabolic syndrome z-score improved -0.9 vs -0.2 placebo (p<0.0001).
  • No new safety signals; adverse events consistent with prior Phase 3 trials.
  • Six posters presented at ECE 2026; none represent regulatory filings or label expansions.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access